Retatrutide Research: What the Evidence Establishes

The shape of the literature

Retatrutide (development code LY3437943) is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. Eli Lilly developed it. A PubMed title search for "retatrutide" returned 76 records on 28 October 2026, and the first peer-reviewed reports date from 2022, so the whole record is under five years old.

Three features define it:

• •It is a sponsor-led literature. The founding preclinical paper and the first-in-human papers have Eli Lilly authors, and every trial listed below was funded by Lilly. Academic investigators are co-authors on the larger trials, but the programme belongs to the developer.
• •Its preclinical base is narrow. The receptor and animal characterisation we cite comes from one paper by the developer. We have not relied on independent replication of it.
• •It describes one clinical formulation. Each human result concerns the sponsor's product, made and controlled for a trial and given under a protocol.

What the molecule is and where its development stands is on the retatrutide identity page. How it is proposed to act is on the retatrutide mechanism page. This page covers what kind of evidence exists, tier by tier.

In vitro findings

The founding paper (Coskun and colleagues, Cell Metabolism, 2022) reports cell-based assays in which cells carrying a single receptor are exposed to the peptide and the response is measured. In that system retatrutide showed balanced activity at the glucagon and GLP-1 receptors and greater activity at the GIP receptor. This is developer-reported data from an assay, and it establishes behaviour in that assay only.

Animal findings

The same paper reports work in obese mice, in which administration was associated with changes in body weight and glycaemic control. The authors attribute part of the effect to glucagon-receptor-mediated energy expenditure acting alongside the GIP and GLP-1 receptor activity.

That is a result in one rodent model from one group. It does not show the same mechanism operates in people, and no other species is covered by the sources cited here.

Human data

The human studies cited on this page are listed below. All were funded by Eli Lilly.

Primary endpoints differ by study: safety and tolerability in the phase 1b study, change in HbA1c in the phase 2 diabetes trial, and change in body weight in TRIUMPH-1, whose sub-studies added pain and sleep-apnoea outcomes. Each paper reports its results against its own prespecified endpoints. We do not reproduce efficacy figures here: they describe a clinical product given under supervision to selected patients, and quoting them beside a research material would read as a claim about that material. The adverse events these trials reported are set out separately on the retatrutide side effects page.

What cannot be concluded

• •That trial results apply to a research vial. The trial product was manufactured and controlled to clinical standards. A research reagent has no such record, and nothing published describes what a research batch contains beyond its own certificate.
• •That a phase 3 report is a licence. We have found no marketing authorisation from the MHRA, the FDA or any other regulator. Lilly has said it plans a first regulatory submission to the US FDA in the first quarter of 2027. That is a company statement, not a regulatory decision.
• •That the record is long. The longest published trials ran 80 weeks. There are no multi-year data.
• •That each receptor's contribution is known in people. One molecule acting on three receptors cannot be taken apart by studying that molecule alone, so statements about what each receptor adds are inferences from related compounds.
• •That a retail description is evidence. Listings that quote trial outcomes beside a research product are borrowing a result that belongs to a different product.

What would need to be studied

• •Independent replication of the receptor pharmacology, outside the developer's laboratories.
• •Safety data longer than 80 weeks.
• •Comparator work that separates the three receptor contributions.
• •Analytical characterisation of non-sponsor material, including identity, sterility and endotoxin. None of the trials above addresses it.

Analytical documentation

Each catalogue vial is its own batch with its own certificate:

What a batch COA for this material reports

The identity and measured purity of the particular batch tested. The reports are in the COA library, and the product pages are 10mg, 20mg and 30mg.

What a COA cannot establish

Biological activity, sterility, endotoxin levels or suitability for any use in people, and nothing about any other batch. The guides to reading a peptide COA and understanding HPLC purity explain the limits. The retatrutide buying guide covers the catalogue side, and the three-way picture with its licensed neighbours is in the retatrutide, tirzepatide and semaglutide comparison.

Key references

• •Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and [...]: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. doi:10.1016/j.cmet.2022.07.013
• •Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. doi:10.1016/S0140-6736(22)02033-5
• •Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
• •Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X
• •Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. 2026. doi:10.1056/NEJMoa2604169
• •Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. doi:10.1016/S0140-6736(26)01861-1
• •Eli Lilly and Company. Retatrutide successful in two additional Phase 3 obesity trials. Press release, 23 July 2026. Company statement, not peer-reviewed.

Scope and laboratory-use boundary

Materials sold on this site are supplied solely for non-clinical in-vitro laboratory research. They must not be ingested, injected, inhaled, applied or otherwise administered to a human or animal.

We do not provide dosing, routes of administration, treatment guidance, cosmetic-use guidance or in-vivo protocols. Preparation, storage and handling must follow a validated institutional SOP, the material documentation and an appropriate risk assessment.